Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ZYRTEC ALLERGY versus CLARITIN REDITABS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ZYRTEC ALLERGY versus CLARITIN REDITABS.
CHILDREN'S ZYRTEC ALLERGY vs CLARITIN REDITABS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cetirizine is a selective antagonist of peripheral H1 histamine receptors, inhibiting histamine-mediated allergic and inflammatory responses.
Loratadine is a selective antagonist of peripheral histamine H1 receptors, reducing allergic response symptoms by inhibiting histamine release from mast cells.
5 mg (1 tablet or 5 mL oral solution) once daily; dosing frequency may be increased to 10 mg once daily (2 tablets or 10 mL) for more severe symptoms.
10 mg orally once daily.
None Documented
None Documented
Terminal half-life 8.5–10.5 hours in children 2–5 years; 9–11 hours in children 6–12 years; 8–9 hours in adults. Clinically, supports once-daily dosing.
Terminal elimination half-life: 8–28 hours (mean ~14 hours for loratadine; active metabolite desloratadine: 14–26 hours). Context: Allows once-daily dosing; half-life extended in hepatic impairment.
Primarily renal (60% unchanged) via tubular secretion; 40% metabolized in liver to inactive metabolites excreted in urine; <1% fecal.
Renal (approximately 40% as metabolites) and fecal (approximately 40% as metabolites). Parent drug and active metabolite (desloratadine) are excreted in urine (27% total) and feces (40% total).
Category C
Category C
Antihistamine
Antihistamine